Pet medication developer Aratana Therapeutics sets terms for $51 million IPO


Shutterstock photo

Aratana Therapeutics, which is focused on the development and commercialization of prescription medication for pets, announced terms for its IPO on Thursday. The Kansas City, KS-based company plans to raise $51 million by offering 4.3 million shares at a price range of $11 to $13. At the midpoint of the proposed range, Aratana Therapeutics would command a market value of $223 million. The company filed for an IPO with a proposed deal size of $58 million in March. 

Aratana Therapeutics, which was founded in 2010 and has yet to generate any revenue, plans to list on the NASDAQ under the symbol PETX. Stifel and Lazard Capital Markets are the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by